213 related articles for article (PubMed ID: 16703728)
1. [Tumor marker tests in bladder cancer].
Feil G; Stenzl A
Actas Urol Esp; 2006 Jan; 30(1):38-45. PubMed ID: 16703728
[TBL] [Abstract][Full Text] [Related]
2. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
[TBL] [Abstract][Full Text] [Related]
3. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
5. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic significance of protein NMP22 in bladder cancer].
Rybotycka Z; Długosz A
Pol Merkur Lekarski; 2015 Jun; 38(228):309-14. PubMed ID: 26098648
[TBL] [Abstract][Full Text] [Related]
7. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
Serretta V; Pomara G; Rizzo I; Esposito E
Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
[TBL] [Abstract][Full Text] [Related]
9. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
10. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
11. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
13. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for detection and surveillance of bladder cancer.
Budman LI; Kassouf W; Steinberg JR
Can Urol Assoc J; 2008 Jun; 2(3):212-21. PubMed ID: 18682775
[TBL] [Abstract][Full Text] [Related]
15. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Lokeshwar VB; Soloway MS
J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
[TBL] [Abstract][Full Text] [Related]
16. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
Gonzalo Rodríguez V; Sanz Justo L; de Miguel Santamaría I; Martínez de Iturrate J; Fernández del Busto E
Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
[TBL] [Abstract][Full Text] [Related]
17. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
18. Urinary markers of bladder carcinoma.
Dey P
Clin Chim Acta; 2004 Feb; 340(1-2):57-65. PubMed ID: 14734196
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.
Toma MI; Friedrich MG; Hautmann SH; Jäkel KT; Erbersdobler A; Hellstern A; Huland H
World J Urol; 2004 Jun; 22(2):145-9. PubMed ID: 14991320
[TBL] [Abstract][Full Text] [Related]
20. [Novel NMP22 quick qualitative analysis (BladderChek NMP22) for the diagnosis of urothelial tumor].
Minagawa T; Nishizawa S; Kamigaito T; Okaneya T
Nihon Hinyokika Gakkai Zasshi; 2006 Jan; 97(1):20-6. PubMed ID: 16485550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
